Developer docs
API playgroundTry for free, no card

Search company profiles

ClavystBio

Full company profile

uuid0003vql

Namestring
ClavystBio
Legal namestring
ClavystBio Pte Ltd
Websiteurl
clavystbio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

ClavystBio is a Singapore-based life sciences investor and venture builder established by Temasek in 2022 to translate Singapore-origin biotech, medtech, and digital health research into globally competitive companies. The firm operates three core programs: a Venture Builder function that identifies and incubates new companies; a Trusted Partner function that forges public-private partnerships (notably with A*STAR, NUS, Duke-NUS, NHIC's CADRE program, and SEEDS Capital); and a physical ecosystem asset, Node 1, a collaborative innovation space at Science Park 1 that hosts ventures graduating from incubators. Through 65LAB, a company-creation vehicle co-founded with Evotec SE and backed by Lightstone Ventures, Leaps by Bayer, and Polaris Partners, ClavystBio funds Singapore academic projects up to US$1.5M each over 18–24 months with the goal of spinning off new companies within 3–5 years.

The portfolio spans 21 named companies across modalities including AAV gene therapy (Nuevocor, Cirrus Therapeutics), multi-payload ADCs (Callio Therapeutics), precision biotherapeutics (Hummingbird Bioscience, Engine Biosciences), cellular therapy (MediSix Therapeutics), bat-biology-derived therapeutics (Paratus Sciences), robotic surgical systems (Biobot Surgical), AI patient monitoring (Respiree), and autophagy-based protein degradation (Automera). Several portfolio companies have achieved FDA, CE, or IND regulatory milestones. The firm also operates a cross-border collaboration with Biosparc (a Temasek/Suzhou Industrial Park life sciences industrial park launching in 2026) and True Light PE to support China-Singapore R&D. Revenue mechanics derive from management fees on funds under management, carried interest on portfolio exits, and modest ecosystem services income from Node 1; specific revenue figures are not publicly disclosed.

Short descriptiontext

ClavystBio is a Singapore-based life sciences investor and venture builder, wholly owned by Temasek, that identifies, incubates, and funds biotech, medtech, and digital health companies from Singapore's academic and translational research pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotech venture builder, medtech investment, digital health venture, company creation
Product category
Life Sciences Venture Capital and Venture Building
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Venture Capital Returns (Carry and Management Fees)
TypeLicensing Royalties
Description

As a life sciences investor and venture builder established by Temasek, ClavystBio generates returns through carried interest on portfolio company exits and management fees on funds under management. It is positioned as a long-term profit-seeking investor targeting a tripling of returns from biotechnology investments.

asia.nikkei.com
2Ecosystem Services
TypeManaged Services
Description

ClavystBio provides Node 1 collaborative workspace and ecosystem convening services to support portfolio and community companies, charging rent and providing shared lab infrastructure, meeting spaces, and operational support.

clavystbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Node 1
Description

Collaborative innovation space for life sciences ventures that have graduated from incubators, offering private suites, graduation spaces, operational support, and community access

clavystbio.com
+2 more records
Core offering1 text field

ClavystBio is a life sciences investor and venture builder that deploys equity capital and operational support to launch and grow early-stage biotech, medtech, and digital health companies from Singapore. It provides venture building services through active incubation, the 65LAB company creation partnership with Evotec and global investors, the Node 1 collaborative innovation space, and partnership facilitation with Singapore's research institutions and government agencies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Multiple portfolio companies achieved major regulatory milestones including FDA 510(k) clearance, IND clearance, and CE marking
+1 more record
Product overview1 text field

ClavystBio is a life sciences investor and venture builder established by Temasek, committed to launching and growing global companies from Singapore. The company operates through venture building services, strategic partnerships, and its collaborative innovation space Node 1. Core offerings include identification and incubation of promising life sciences innovations through 65LAB (a partnership with Evotec and global investors), investment and growth capital deployment, partnership facilitation with academic institutions and industry, and provision of lab infrastructure at Node 1. The portfolio encompasses therapeutics companies (Nuevocor with gene therapy for cardiomyopathies, Cirrus Therapeutics with AAV ocular gene therapy, Callio Therapeutics with multi-payload ADCs, Hummingbird Bioscience with precision biotherapeutics), MedTech/Digital Health companies (Biobot Surgical with robotic surgical systems, Respiree with AI-powered 1Bio disease management platform), and enabling infrastructure companies (NSG BioLabs with shared lab facilities).

Product and service4 records
1Venture Builder Services
CategoryVenture Building and Incubation
2Trusted Partner Services
CategoryEcosystem Partnership Services
3Node 1
CategoryCollaborative Innovation Space
465LAB
CategoryVenture Creation Vehicle
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-10
Description

ClavystBio and A*STAR signed a two-year MoU to create and grow MedTech ventures in Singapore. The partnership co-creates new ventures from research, advances MedTech product development through MedTech Catapult and DxD Hub national initiatives, accelerates commercial readiness in diagnostics and digital health, and strengthens Singapore's MedTech ecosystem. The partnership leverages ClavystBio's venture investing and industry relationships alongside A*STAR's deep scientific expertise and productisation platforms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-05
Description

65LAB is a unique company creation vehicle co-founded by Lightstone Ventures and Evotec SE, with ClavystBio, Leaps by Bayer, Polaris Partners, and Polaris Innovation Fund as investor partners. It identifies promising academic research from A*STAR, NUS, and Duke-NUS Medical School, provides up to US$1.5 million in project funding over 18-24 months, and evaluates successful projects for further investment and new company formation. Evotec contributes its end-to-end R&D platform and Expert-in-Residence support. 65LAB is the first collaboration of its kind in Singapore and Asia.

3Biosparc (Temasek / Suzhou Industrial Park)
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

A tripartite strategic collaboration between Biosparc, ClavystBio, and True Light PE to support innovators from both China and Singapore in advancing research, clinical development, and early commercialization. The partnership leverages each party's networks and capabilities to strengthen cross-border R&D and establish a pipeline for project landing and growth. Biosparc is a life sciences industrial park on Sangtian Science Island in Suzhou, under development with an expected launch in 2026.

clavystbio.com
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

ClavystBio is a partner of NHIC's CADRE (Clinical Advancement and Development for Research, Entrepreneurship and Enterprise) programme. NHIC works with Public Health Institutions across Singapore to identify and commercialize promising clinical innovations. ClavystBio supports healthtech projects with Public Healthcare Clusters in early-stage commercialization through venture co-creation, technology development, co-investment, and nurturing of tri-competent healthtech talent.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Baker Bros. Advisors
TypeDirect peer
Description

Biotech-focused investment advisor with deep, concentrated positions in clinical-stage life sciences companies — comparable long-duration, fundamentals-driven life sciences investment orientation.

TypeDirect peer
Description

The closest peer: a biotech venture creation firm that originates and builds new companies from scientific research, with active incubation and dedicated operating support — directly mirrors ClavystBio's venture builder model.

TypeDirect peer
Description

Long-standing biotech-focused VC that partners with founders to build companies from breakthrough science across therapeutics and platforms — directly comparable investment mandate and capital scale.

TypeDirect peer
Description

Biotech and healthcare VC that co-invests in ClavystBio's 65LAB programme and runs its own venture creation activities — directly comparable life sciences focus and co-investment profile.

TypeDirect peer
Description

Healthcare-dedicated investment firm spanning venture, growth, and public equities across therapeutics, medical devices, and diagnostics — directly comparable life sciences investment focus.

TypeDirect peer
Description

Biotech-focused VC that actively creates, builds, and funds new life sciences companies from inception through exit — operates a venture creation model analogous to ClavystBio's 65LAB.

TypeDirect peer
Description

Early-stage life sciences VC that creates and funds biotech companies from academic and startup-stage science — comparable early-stage biotech venture creation model.

TypeDirect peer
Description

Dedicated life sciences investment firm running a crossover fund that supports biotech companies from formation through IPO — comparable institutional life sciences investment model.

9Leaps by Bayer
TypeDirect peer
Description

Bayer's life sciences venture arm investing in breakthrough biotech, medtech, and digital health — co-invests in ClavystBio's 65LAB and shares a venture-stage life sciences investment mandate.

TypeDirect peer
Description

Tech-rooted VC with a dedicated Bio fund investing across biotech, digital health, and healthcare infrastructure — comparable in its active partnership approach and breadth across life sciences sub-sectors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment18 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ClavystBio

Life Sciences Venture Capital and Venture Buildingclavystbio.com

ClavystBio is a Singapore-based life sciences investor and venture builder, wholly owned by Temasek, that identifies, incubates, and funds biotech, medtech, and digital health companies from Singapore's academic and translational research pipeline.

What ClavystBio does

ClavystBio is a Singapore-based life sciences investor and venture builder established by Temasek in 2022 to translate Singapore-origin biotech, medtech, and digital health research into globally competitive companies. The firm operates three core programs: a Venture Builder function that identifies and incubates new companies; a Trusted Partner function that forges public-private partnerships (notably with A*STAR, NUS, Duke-NUS, NHIC's CADRE program, and SEEDS Capital); and a physical ecosystem asset, Node 1, a collaborative innovation space at Science Park 1 that hosts ventures graduating from incubators. Through 65LAB, a company-creation vehicle co-founded with Evotec SE and backed by Lightstone Ventures, Leaps by Bayer, and Polaris Partners, ClavystBio funds Singapore academic projects up to US$1.5M each over 18–24 months with the goal of spinning off new companies within 3–5 years.

The portfolio spans 21 named companies across modalities including AAV gene therapy (Nuevocor, Cirrus Therapeutics), multi-payload ADCs (Callio Therapeutics), precision biotherapeutics (Hummingbird Bioscience, Engine Biosciences), cellular therapy (MediSix Therapeutics), bat-biology-derived therapeutics (Paratus Sciences), robotic surgical systems (Biobot Surgical), AI patient monitoring (Respiree), and autophagy-based protein degradation (Automera). Several portfolio companies have achieved FDA, CE, or IND regulatory milestones. The firm also operates a cross-border collaboration with Biosparc (a Temasek/Suzhou Industrial Park life sciences industrial park launching in 2026) and True Light PE to support China-Singapore R&D. Revenue mechanics derive from management fees on funds under management, carried interest on portfolio exits, and modest ecosystem services income from Node 1; specific revenue figures are not publicly disclosed.

ClavystBio firmographics

Firmographics
Name
ClavystBio
Legal name
ClavystBio Pte Ltd
Website
https://clavystbio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
ClavystBio is a Singapore-based life sciences investor and venture builder, wholly owned by Temasek, that identifies, incubates, and funds biotech, medtech, and digital health companies from Singapore's academic and translational research pipeline.
Ownership category
akta.pro rank

Where ClavystBio is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

ClavystBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Venture Capital Returns (Carry and Management Fees): As a life sciences investor and venture builder established by Temasek, ClavystBio generates returns through carried interest on portfolio company exits and management fees on funds under management. It is positioned as a long-term profit-seeking investor targeting a tripling of returns from biotechnology investments.
  2. Ecosystem Services: ClavystBio provides Node 1 collaborative workspace and ecosystem convening services to support portfolio and community companies, charging rent and providing shared lab infrastructure, meeting spaces, and operational support.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

ClavystBio product offering

Product offering

Core offering

ClavystBio is a life sciences investor and venture builder that deploys equity capital and operational support to launch and grow early-stage biotech, medtech, and digital health companies from Singapore. It provides venture building services through active incubation, the 65LAB company creation partnership with Evotec and global investors, the Node 1 collaborative innovation space, and partnership facilitation with Singapore's research institutions and government agencies.

Product overview

ClavystBio is a life sciences investor and venture builder established by Temasek, committed to launching and growing global companies from Singapore. The company operates through venture building services, strategic partnerships, and its collaborative innovation space Node 1. Core offerings include identification and incubation of promising life sciences innovations through 65LAB (a partnership with Evotec and global investors), investment and growth capital deployment, partnership facilitation with academic institutions and industry, and provision of lab infrastructure at Node 1. The portfolio encompasses therapeutics companies (Nuevocor with gene therapy for cardiomyopathies, Cirrus Therapeutics with AAV ocular gene therapy, Callio Therapeutics with multi-payload ADCs, Hummingbird Bioscience with precision biotherapeutics), MedTech/Digital Health companies (Biobot Surgical with robotic surgical systems, Respiree with AI-powered 1Bio disease management platform), and enabling infrastructure companies (NSG BioLabs with shared lab facilities).

Differentiator

Problem solved

Functional benefit

Brands

  • Node 1: Collaborative innovation space for life sciences ventures that have graduated from incubators, offering private suites, graduation spaces, operational support, and community access
  • 65LAB
  • Biosparc

Products and services

  • Venture Builder Services
  • Trusted Partner Services
  • Node 1
  • 65LAB

Quantifiable outcome

  • Multiple portfolio companies achieved major regulatory milestones including FDA 510(k) clearance, IND clearance, and CE marking
  • +1 more outcomes

Companies that use ClavystBio

Customer profile

Segments3 records

Ideal customer profiles3 records

ClavystBio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature1 record

ClavystBio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and secondary.

  • A*STAR (Agency for Science, Technology and Research)coreStrategic or Co-development Partner · 10 June 2025ClavystBio and A*STAR signed a two-year MoU to create and grow MedTech ventures in Singapore. The partnership co-creates new ventures from research, advances MedTech product development through MedTech Catapult and DxD Hub national initiatives, accelerates commercial readiness in diagnostics and digital health, and strengthens Singapore's MedTech ecosystem. The partnership leverages ClavystBio's venture investing and industry relationships alongside A*STAR's deep scientific expertise and productisation platforms.
  • 65LAB (Evotec, Lightstone Ventures, Leaps by Bayer, Polaris Partners)coreStrategic or Co-development Partner · 5 October 202365LAB is a unique company creation vehicle co-founded by Lightstone Ventures and Evotec SE, with ClavystBio, Leaps by Bayer, Polaris Partners, and Polaris Innovation Fund as investor partners. It identifies promising academic research from A*STAR, NUS, and Duke-NUS Medical School, provides up to US$1.5 million in project funding over 18-24 months, and evaluates successful projects for further investment and new company formation. Evotec contributes its end-to-end R&D platform and Expert-in-Residence support. 65LAB is the first collaboration of its kind in Singapore and Asia.
  • Biosparc (Temasek / Suzhou Industrial Park)secondaryStrategic or Co-development PartnerA tripartite strategic collaboration between Biosparc, ClavystBio, and True Light PE to support innovators from both China and Singapore in advancing research, clinical development, and early commercialization. The partnership leverages each party's networks and capabilities to strengthen cross-border R&D and establish a pipeline for project landing and growth. Biosparc is a life sciences industrial park on Sangtian Science Island in Suzhou, under development with an expected launch in 2026.
  • NHIC (National Health Innovation Centre Singapore)secondaryStrategic or Co-development PartnerClavystBio is a partner of NHIC's CADRE (Clinical Advancement and Development for Research, Entrepreneurship and Enterprise) programme. NHIC works with Public Health Institutions across Singapore to identify and commercialize promising clinical innovations. ClavystBio supports healthtech projects with Public Healthcare Clusters in early-stage commercialization through venture co-creation, technology development, co-investment, and nurturing of tri-competent healthtech talent.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

ClavystBio competitors and assessment

Company assessment

Direct peers

  • Baker Bros. Advisors: Biotech-focused investment advisor with deep, concentrated positions in clinical-stage life sciences companies — comparable long-duration, fundamentals-driven life sciences investment orientation.
  • Flagship Pioneering: The closest peer: a biotech venture creation firm that originates and builds new companies from scientific research, with active incubation and dedicated operating support — directly mirrors ClavystBio's venture builder model.
  • ARCH Venture Partners: Long-standing biotech-focused VC that partners with founders to build companies from breakthrough science across therapeutics and platforms — directly comparable investment mandate and capital scale.
  • Polaris Partners: Biotech and healthcare VC that co-invests in ClavystBio's 65LAB programme and runs its own venture creation activities — directly comparable life sciences focus and co-investment profile.
  • OrbiMed: Healthcare-dedicated investment firm spanning venture, growth, and public equities across therapeutics, medical devices, and diagnostics — directly comparable life sciences investment focus.
  • Atlas Venture: Biotech-focused VC that actively creates, builds, and funds new life sciences companies from inception through exit — operates a venture creation model analogous to ClavystBio's 65LAB.
  • 5AM Ventures: Early-stage life sciences VC that creates and funds biotech companies from academic and startup-stage science — comparable early-stage biotech venture creation model.
  • RA Capital Management: Dedicated life sciences investment firm running a crossover fund that supports biotech companies from formation through IPO — comparable institutional life sciences investment model.
  • Leaps by Bayer: Bayer's life sciences venture arm investing in breakthrough biotech, medtech, and digital health — co-invests in ClavystBio's 65LAB and shares a venture-stage life sciences investment mandate.
  • Andreessen Horowitz (a16z Bio): Tech-rooted VC with a dedicated Bio fund investing across biotech, digital health, and healthcare infrastructure — comparable in its active partnership approach and breadth across life sciences sub-sectors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ClavystBio social profiles

Digital presence

ClavystBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ClavystBio leadership team

Management profile

Number of profiles

Profiles6 records

ClavystBio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ClavystBio M&A and investment

M&A and investment

M&A

Investments18 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ClavystBio

What does ClavystBio do?

ClavystBio is a life sciences investor and venture builder that deploys equity capital and operational support to launch and grow early-stage biotech, medtech, and digital health companies from Singapore. It provides venture building services through active incubation, the 65LAB company creation partnership with Evotec and global investors, the Node 1 collaborative innovation space, and partnership facilitation with Singapore's research institutions and government agencies.

Is ClavystBio a public or private company?

ClavystBio is a private company. It is classified as corporate owned and is currently operating.

When was ClavystBio founded?

ClavystBio was founded in 2022. It employs 11 to 50 people.

Where is ClavystBio based?

ClavystBio is headquartered in Singapore, Singapore, in the Asia region.

How does ClavystBio make money?

Two revenue lines are on record. Venture Capital Returns (Carry and Management Fees) is the primary driver. The others are ecosystem Services.

Who are ClavystBio's main competitors?

Direct peers on record are Baker Bros. Advisors, Flagship Pioneering, ARCH Venture Partners, Polaris Partners, OrbiMed, Atlas Venture, 5AM Ventures, RA Capital Management, Leaps by Bayer and Andreessen Horowitz (a16z Bio).

Does ClavystBio have an API?

No public API is recorded for ClavystBio.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical BuyerZenflow raises USD 52M in Series D financing roundZenflow closed a $52 million Series D round led by Cook Medical, with participation from ClavystBio and existing investors, plus venture debt from HSBC and Trinity Capital. The proceeds will accelerate the commercial launch of the Zenflow Spring System after FDA PMA approval in December 2025. The company also signed an exclusive US distribution agreement with Cook Medical.BioSpaceRespiree Extends Series A Syndicate with Addition of International Investors to Support Continued Global GrowthRespiree announced that ARKRAY & PARTNERS and Bizedge Capital joined its Series A syndicate, led by We Venture Capital and ClavystBio. The company will use the funds to expand its global commercial team and US presence. Respiree's AI platform is available in the US, Australia, and Asia-Pacific.European BiotechnologyLeyden Labs reveals RIGImmune acquisition with Phase 1 dataLeyden Labs reported positive Phase 1 results for intranasal RIG-101 and disclosed its acquisition of RIGImmune earlier in 2026. The drug was safe and well-tolerated, inducing interferons in asthma patients. The next trial will challenge patients with rhinovirus, with completion expected in February 2027.GlobeNewswireCirrus Therapeutics Strengthens Its Position as a Next-Generation Global Ocular Immunology Leader with Singapore Eye Research Institute (SERI) Collaboration and Additional FinancingCirrus Therapeutics announced a collaboration with Singapore Eye Research Institute and Duke-NUS Medical School to advance ocular immunology research. The company also expanded its investor syndicate, including Cedars Sinai Intellectual Property Company, raising $14.7 million in seed financing. Its lead program is a gene therapy to restore IRAK-M in geographic atrophy patients.IncubeesBiobot Surgical secures $15 M to bring Robotic Prostate Cancer platform to the U.S. – IncubeesBiobot Surgical, a Singapore-based medical technology startup, raised S$20 million (approximately $15.4 million) in a funding round led by ClavystBio with participation from ZIG Ventures. The funding will accelerate deployment of the company's Mona Lisa platform—which combines robotic needle guiding with MRI-ultrasound image fusion for targeted prostate biopsy and ablation—in foreign markets, particularly the United States. As part of its U.S. commercialization strategy, Biobot has partnered with Fogarty Innovation to identify priority clinical markets and accelerate technology adoption among healthcare providers.TNGlobalSingapore's Biobot Surgical raises $15M to expand robotic prostate cancer platform into US marketBiobot Surgical raised S$20 million ($15.4 million) led by ClavystBio and ZIG Ventures to expand its robotic prostate cancer platform into the US market. The funding will accelerate adoption of its Mona Lisa system, which has deployed over 80 systems globally and supported more than 30,000 patients.Tech in AsiaSingapore medtech firm Biobot raises $15.4m for US pushBiobot Surgical raised S$20 million (US$15.4 million) in a round led by ClavystBio and ZIG Ventures. The funding will support US commercialization of its Mona Lisa prostate cancer platform, which has over 80 systems deployed globally. The company will partner with Fogarty Innovation for US commercialization.European BiotechnologyLeyden Labs adds €40m for intranasal flu preventionLeyden Labs raised €40m from investors including the Gates Foundation and ClavystBio to advance its intranasal antibody spray for influenza prevention. The funding supports its PanFlu program, which uses CR9114, with early human safety data from 143 volunteers. The company still needs clinical efficacy proof.FinSMEsLeyden Labs Raises $40M in FundingLeyden Laboratories raised $40M in funding led by the European Innovation Council Fund, Invest-NL, Gates Foundation, and ClavystBio. The company will use the funds to expand operations and development efforts. It develops nasal sprays to protect against respiratory viruses like influenza and coronaviruses.MorningstarGlobally Recognized Impact Investors Back Leyden Labs’ Mission to Transform Protection Against Respiratory Viruses with €40 Million InvestmentLeyden Labs announced a €40 million investment from the EIC Fund, Invest-NL, Gates Foundation, and others. The funding supports its nasal spray platform for respiratory virus protection, with Ben Verwaayen joining the supervisory board. The company aims to advance clinical development and global access.